Johnson & Johnson traded down 0.36% on Monday, hitting $62.1172. Johnson & Johnson has a 52-week low of $59.08 and a 52-week high of $68.05. The company has a market cap of $170.6 billion and a price-to-earnings ratio of 17.09.
Johnson & Johnson last posted its quarterly earnings results on Tuesday, April 17th. The company reported $1.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.03. The company’s revenue for the quarter was down .2% on a year-over-year basis. Analysts expect that Johnson & Johnson will post $1.25 EPS next quarter.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Johnson & Johnson in a research note to investors on Friday, April 27th. They now have a $68.00 price target on the stock. Finally, analysts at UBS AG (NYSE: UBS) cut their price target on shares of Johnson & Johnson from $71.00 to $70.00 in a research note to investors on Wednesday, April 18th. They now have a “buy” rating on the stock.
Johnson & Johnson is a holding company. The Company, along with its subsidiaries, is engaged in the research and development, manufacture and sale of a range of products in the healthcare field.